Chelsea Therapeutics International (CHTP) Posts Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Chelsea Therapeutics International (NASDAQ: CHTP) announced its earnings results on Thursday. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.05.
Several analysts have also recently commented on the stock. Analysts at UBS AG upgraded shares of Chelsea Therapeutics International from a “hold” rating to a “buy” rating in a research note to investors on Wednesday, February 20th. They noted that the move was a valuation call. On a related note, analysts at Wedbush reiterated an “outperform” rating on shares of Chelsea Therapeutics International in a research note to investors on Wednesday, February 20th. They now have a $7.00 price target on the stock, up previously from $5.00. Finally, analysts at Needham & Company upgraded shares of Chelsea Therapeutics International from a “hold” rating to a “buy” rating in a research note to investors on Wednesday, February 20th.
Four analysts have rated the stock with a buy rating, and one has assigned a hold rating to the company. Chelsea Therapeutics International has a consensus rating of “buy” and a consensus target price of $4.50.
Shares of Chelsea Therapeutics International (CHTP) traded up 2.26% during mid-day trading on Thursday, hitting $1.81. Chelsea Therapeutics International (CHTP) has a one year low of $0.70 and a one year high of $4.21. The stock’s 50-day moving average is currently $1.09. The company’s market cap is $121.3 million.
Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.